Figure 5
Analysis of 131I-ANA biodistribution in vivo and inhibition of tumor growth (a) Biodistribution of 131I-ANAs in tissue of mice with PC3 xenografts (n = 5). The results are presented as the mean ± SD (error bars). (b) Blood clearance and tumor concentration of 131I-ANAs with time. (c) Tumor growth in nude mice bearing PC3 tumor xenografts; mean ± SD, n = 10 in the 0.9% NaCl and ANA groups, n = 30 in the 131I-ANA group (****P < 0.0001, 131I-ANAs vs. 0.9% NaCl; ***P < 0.001, 131I-ANAs vs. ANA, two-way ANOVA with Tukey's multiple comparisons test. The tumor growth inhibition rates were expressed as the mean and SE (13.21 ± 6.79%, 131I-ANAs vs. ANA; 28.33 ± 5.01%, 131I-ANAs vs. 0,9% NaCl and 17.41 ± 5.18%, ANAs vs. 0,9% NaCl) (d) Kaplan‒Meier survival curve showing the effects of 131I-ANAs on the median survival of PC3 tumor-bearing mice (***P = 0.0006; GraphPad Prim 8; log-rank (Mantel‒Cox) test; chi-square 14.89, df = 2). Compared with 0.9% NaCl (control), treatment with 131I-ANAs or ANAs resulted in a 1.83- (64 vs. 35 days) or 1.43-fold (50 vs. 35 days) increase in median survival, respectively (GraphPad 8, survival). (e), (f) Light micrograph of HE staining (200 ×) in liver, which showed hemorrhagic zones and mild degeneration (arrow white) at 72 and 168 h after injection. (g), (h) Light micrograph of HE staining (200 ×) of kidney, which showed replicated endothelial cells of the artery (gray white) at 72 and 168 h after injection. (i), (j) Light micrograph of HE staining (400 ×) of the tumor, which showed large nucleoli, bizarre nucleoli, and abnormal mitotic nuclei (black arrow) at 72 and 168 h after injection. Notes: White arrow: hemorrhagic zones; Gray arrow: reactive inflammation; Black arrow: large nucleoli, bizarre nuclei, abnormal mitotic nuclei.
